1. A Global Clinical Trial Strategy Guide Centered on South Korea

South Korea is not merely a country for enrolling additional patients in global clinical trial projects. It serves as a strategic clinical development hub equipped with advanced medical infrastructure, highly experienced investigators, and hospital-centric clinical trial execution capabilities, allowing for the parallel processing of MFDS (Ministry of Food and Drug Safety) and IRB (Institutional Review Board) reviews.

 

As of 2024, South Korea ranked 6th globally in pharmaceutical company-sponsored clinical trials, accounting for a 3.46% share of total protocols. Notably, Seoul was highly evaluated as the world’s 2nd largest city for pharmaceutical company-sponsored clinical trials.

 

However, the success of a clinical trial is not determined solely by the choice of country. Successful development requires initial safety and PK/PD-based decision-making in Phase I, proof-of-concept (PoC) and dose optimization in Phase II, and confirmatory efficacy, safety, and large-scale multi-center execution capabilities in Phase III. Clinical strategies for each phase must be connected into a single organic operational system alongside regulatory responses, patient recruitment, data integrity, quality management, and CRO governance.

 

2. Why Clinical Trials are Crucial in Drug Development

Clinical trials are a core stage that rigorously verifies whether a new drug candidate demonstrates an acceptable safety profile and clinical efficacy in humans. While non-clinical studies confirm toxicity and pharmacological actions, clinical trials sequentially evaluate dosage, safety, efficacy, and the risk-benefit ratio in healthy volunteers or patients.

 

Major regulatory agencies such as the FDA, EMA, and MFDS base their approval decisions not only on the scientific validity of clinical data but also primarily on the protection of trial subjects, data reliability and integrity, and protocol compliance.

 

General pharmaceutical clinical development, as described by the FDA, begins with an initial Phase I involving approximately 20 to 100 participants.

 

It then progresses through Phase II with up to hundreds of participants, eventually advancing to large-scale Phase III trials targeting about 300 to 3,000 patients.

 

In the clinical trial operational environment as of 2026, simply declaring “GCP compliance” is insufficient. The ICH E6(R3) guideline emphasizes integrating Quality by Design (QbD), risk-proportionate quality management, data governance, the utilization of cutting-edge technology, and subject protection principles throughout the entire lifecycle of a clinical trial. Particularly, in conjunction with ICH E8(R1), it is critical to proactively identify Critical-to-Quality (CtQ) factors that decisively impact quality and to design a control system proportionate to those risks.

 

Therefore, from the point of protocol design, it is necessary to clearly define what elements might threaten patient safety or the reliability of primary endpoints, how these will be prevented, and how the effectiveness of the controls will be verified.

 

(For reference, as of July 14, 2026, there are 593,857 studies registered on ClinicalTrials.gov, of which 453,135 are interventional studies, illustrating the intense global competition to secure patients and research institutions.)

 

3. Step-by-Step Clinical Trial Success Strategies

1) Phase I: A Strategic Approach Beyond Simple Safety Confirmation

 

Phase I is the stage where the investigational drug is administered to humans for the first time to evaluate safety, tolerability, pharmacokinetics (PK), and initial pharmacodynamics (PD).

It typically involves 20 to 100 volunteers, starting with healthy subjects, although in special cases like oncology drugs, it may be conducted on patients.

The core of Phase I is not merely exploring the ‘Maximum Tolerated Dose (MTD)’ but establishing exposure-response relationships and initial risk-benefit information for decision-making in the next development phase.

Particularly in oncology drug development, an advanced strategy is required to select subsequent doses by comprehensively considering the Recommended Phase 2 Dose (RP2D), biological activity, target engagement, and biomarker signals, rather than relying solely on a single MTD determination. From an operational perspective, the speed of safety data review is vital in Phase I. The entire process—from data entry to PK sample processing and safety review—must be tightly integrated within very short cycles, meaning the partner CRO must be capable of flawlessly controlling these schedules within a single timeline.

2) Phase II: Proof of Concept (PoC) and Dose Optimization Determine Value

 

Phase II is the stage for confirming preliminary efficacy and establishing appropriate dosage and administration strategies in an actual patient population. Involving tens to hundreds of patients, this phase serves as a critical watershed determining whether to proceed to Phase III, which requires large-scale capital investment.

A successful Phase II must go beyond simple statistical significance (p-value). Meaningful effect size, appropriate control groups, biomarkers, and interim analyses must be precisely defined in alignment with the development objectives.

One of the greatest risks is when the patient population defined in the protocol does not match the actual patient population in clinical settings. To prevent development delays, feasibility reviews must move beyond simple patient count estimates to comprehensively evaluate the number of eligible patients upon applying inclusion/exclusion criteria, standard care pathways, and the burden of patient visits, thereby enhancing accessibility.

3) Phase III: Simultaneous Design of Confirmatory Evidence and Operational Scalability

 

Phase III is the stage to confirm treatment efficacy and safety in a larger patient population (typically 300 to 3,000 or more) and to establish core evidence for a New Drug Application (NDA).

Since tens or hundreds of sites participate in this stage, the project’s success is determined not only by the protocol’s validity but also by its ‘operational scalability’.

As tasks such as investigator training, consistency of evaluations, Investigational Medicinal Product (IMP) supply, and Trial Master File (TMF) management become exponentially complex, it is essential to efficiently control these through the adoption of Risk-Based Quality Management (RBQM) and centralized monitoring.

When including South Korean sites in global Phase III trials, it is necessary to seamlessly align MFDS and domestic IRB requirements, contracts, language, and safety reporting systems with the local Korean environment, while strictly maintaining global protocol standards. This represents the true value that an excellent South Korean CRO should provide.

4. Why Global Drug Development Focuses on South Korea

South Korea recorded the 6th position worldwide in pharmaceutical company-sponsored clinical trials and a 3.46% protocol share in 2024, establishing itself as a core multi-regional clinical trial country in Asia.

 

The core of its competitiveness: Accumulated investigator experience centered on large university hospitals, efficient diagnostic and therapeutic infrastructure, and an advanced digital healthcare environment are South Korea’s greatest strengths.

 

Particularly in oncology, rare diseases, and immunological disorders, where patient screening is challenging, the outstanding multidisciplinary collaboration systems of Korean hospitals enable rapid patient enrollment and successful study execution.

 

5. South Korean Regulatory Environment (MFDS·IRB) and Optimized Operational Strategy

Conducting pharmaceutical clinical trials in South Korea requires Investigational New Drug (IND) approval from the MFDS and Institutional Review Board (IRB) review at each hospital.

 

A powerful advantage of South Korea is that the IND review (approximately 30 working days) and the IRB review (approximately 3 weeks) can be conducted in parallel. As of 2025, the number of domestic pharmaceutical clinical trial approvals reached 783, showing continuous growth.

 

However, faster regulatory reviews do not automatically accelerate the First Patient In (FPI) milestone. True time reduction is only possible when complex practical processes—such as site contracts, document translation, vendor verification, and IMP import and distribution—are tightly managed as a single, integrated ‘Start-up Plan’.

 

6. Essential Checklists for a Successful CRO Partnership

Modern CROs are not merely personnel dispatch agencies. They are integrated partners that translate scientific design intentions into actual operations and connect regulatory agencies, investigators, data, and vendors into a single powerful management system. When selecting a partner, be sure to check the following:

 

1. Do they have abundant experience in the relevant therapeutic area and development phase?
2. Do they possess MFDS Q&A capabilities and strong site relationships with clinical trial institutions?
3. Beyond simple price competitiveness, do they have risk control capabilities, issue resolution speed, and an independent Quality Assurance (QA) system? (The lowest initial quote does not necessarily mean final development cost savings.)

 

Table 1. Comparison of Phase I–III Strategies

Phase	Primary Objective	Typical Sample Size	Key Design Questions	Key Operational Risks	Key CRO Role
Phase I	Safety, tolerability, PK/PD, dose exploration	Approx. 20–100 subjects	Are starting doses and escalation rules appropriate? Are stopping criteria clear?	Delayed response to safety signals, delayed PK data	Early regulatory response, cohort operations, safety/PK data flow management
Phase II	PoC, dose optimization, preliminary efficacy	Tens to hundreds of subjects	subjects   Are the patient population and endpoints suitable for development decision-making?	High screen failure rates, incorrect effect size assumptions	feasibility, recruitment, data review, adaptive operation
Phase III	Confirmatory efficacy and safety, evidence for approval	Hundreds to thousands of subjects	Can multi-center variability be controlled while maintaining global standards?	Site variability, vendor complexity, delayed reconciliation	Multi-center PM, RBQM, vendor governance, TMF/DB lock/CSR support

 

 

Table 2. South Korea Clinical Trials Strategic Indicators

Indicator	Latest Confirmed Figures	Strategic Significance
2024 South Korea Global Ranking in Pharma-Sponsored Clinical Trials	6th	A mature clinical trial market suitable for inclusion in global development portfolios
2024 South Korea Protocol Share	3.46%	Top-tier global research execution foundation
2024 Seoul City Ranking	2nd worldwide	A clinical hub with a high concentration of major research institutions and patient accessibility
MFDS IND Typical Review Period	Approx. 30 working days	Start-up optimization is possible through parallel preparation with the IRB
IRB Typical Review Period	Approx. 3 weeks	Must be conducted in parallel with contracts, documents, and vendor readiness
2025 Domestic Clinical Trial Approvals	783 cases	An indicator demonstrating sustained research demand and the scale of the clinical trial ecosystem

 

7. Core Paradigm of Global Clinical Trials After 2026: ICH E6(R3)

A change that must be proactively addressed in future clinical trial strategies is ICH E6(R3). The EMA has already been applying the principles and Annex 1 since July 2025, and Annex 2, which deals with non-traditional designs (such as DCTs), is scheduled to be applied from January 2027. The FDA is also strongly demanding a flexible, risk-based approach and Quality by Design (QbD).

 

Moving forward, simply increasing the frequency of monitoring is not the solution. It is essential to collaborate with a partner equipped with next-generation capabilities to accurately identify critical risks (CtQ), operate control systems proportionate to risk levels, and prove this with clear data.

 

8. Frequently Asked Questions (FAQ)

Q1. What is the greatest advantage of conducting clinical trials in South Korea?

 

A: The presence of an outstanding investigator and large healthcare institution network with abundant multi-regional clinical trial experience, coupled with an efficient Start-up structure that allows for parallel reviews by the MFDS and IRBs. However, to actually accelerate progress, rigorous integrated plan management is essential.

 

Q2. What is the most important capability when selecting a CRO for Phase I trials?

 

A: The operational capability to rapidly and accurately link early safety decision-making with PK data flows. The CRO must be able to flawlessly control everything from cohort operations to dose escalation decisions within a single timeline.

 

Q3. What is the most critical point to note when including South Korea in a global Phase III trial?

 

A: While strictly maintaining the primary endpoints and analysis criteria of the global protocol, it is vital to flexibly localize practical workflows—such as Korean Informed Consent Forms (ICF), site contracts, and IMP supply—to fit South Korean regulations and environments.

 

Design Your Clinical Trial Success in South Korea with SYMYOO

 

Are you planning to conduct successful clinical trials in the Korean market, or aiming to include Korean sites in global trials? Rather than starting operations after the protocol is finalized, reviewing feasibility and regulatory strategies in Korea alongside SYMYOO’s team of experts from the early development stages is the path to significantly reducing time and costs. Through close consulting in the early stages, preemptively control potential risks and enjoy the benefits of rapid patient enrollment.

 

[Request a Quote / Consultation]

 

Do you need customized CRO estimates or want to execute a clinical trial in South Korea? Please share your clinical phase, indications, target patient population, and expected timeline with the SYMYOO expert team. We will promptly propose the optimal solution and a reasonable quote for the success of your project.

 

[Subscribe to the SYMYOO Newsletter]

 

Be the first to receive global clinical development insights, MFDS regulatory trends, and leading CRO operational strategies to boost your global competitiveness.